MRNA Jun 2024 200.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:57AM EDT. Market open.
| Previous close | 0.1100 |
| Open | 0.0300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 200.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0300 - 0.1100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksAnalysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
Investor's Business DailyAnalysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
© 2024 Yahoo. All rights reserved.